Bortezomib-induced skin eruption.
Bortezomib (Velcad) is a proteasome inhibitor recently developed and mainly used for the treatment of multiple myeloma. Bortezomib represents a novel class of drugs functioning as proteasome inhibitors. Skin complications of bortezomib treatment are very frequent but poorly characterized. We describe the case of a patient who developed erythematous and edematous plaques after treatment with bortezomib. This case illustrates one of the potential reactions associated with bortezomib administration and underlines the need to recognize and report cutaneous side effects of this new drug.
Sanchez-Politta
S
S
Department of Dermatology and Venereology, University Hospital and Medical School of Geneva, Geneva, Switzerland.
Favet
L
L
Kerl
K
K
Dietrich
P-Y
PY
Piguet
V
V
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000473:pathology
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib